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Abstract
Background: Preliminary evidence suggests that patients
with atrial fibrillation (AF) detected after stroke (AFDAS) may
have a lower prevalence of cardiovascular comorbidities and
lower risk of stroke recurrence than AF known before stroke
(KAF). Objective: We performed a systematic search and meta-analysis to compare the characteristics of AFDAS and KAF.
Methods: We searched PubMed, Scopus, and EMBASE for articles reporting differences between AFDAS and KAF until
June 30, 2021. We performed random- or fixed-effects metaanalyses to evaluate differences between AFDAS and KAF in
demographic factors, vascular risk factors, prevalent vascular comorbidities, structural heart disease, stroke severity, insular cortex involvement, stroke recurrence, and death. Results: In 21 studies including 22,566 patients with ischemic
stroke or transient ischemic attack, the prevalence of coronary artery disease, congestive heart failure, prior myocardial infarction, and a history of cerebrovascular events was
significantly lower in AFDAS than KAF. Left atrial size was
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smaller, and left ventricular ejection fraction was higher in
AFDAS than KAF. The risk of recurrent stroke was 26% lower
in AFDAS than in KAF. There were no differences in age, sex,
stroke severity, or death rates between AFDAS and KAF.
There were not enough studies to report differences in insular cortex involvement between AF types. Conclusions: We
found significant differences in the prevalence of vascular
comorbidities, structural heart disease, and stroke recurrence rates between AFDAS and KAF, suggesting that they
constitute different clinical entities within the AF spectrum.
PROSPERO registration number is CRD42020202622.
© 2021 The Author(s).
Published by S. Karger AG, Basel

Introduction

Evidence from clinical and experimental research suggests that atrial fibrillation (AF) detected after stroke (AFDAS) is different from known AF (KAF) before stroke
occurrence [1, 2]. It has been hypothesized that detection
bias resulting from prolonged cardiac monitoring after
stroke may lead to the detection of low-risk AFDAS that
may not always have a causal role [1]. Also, neurogenic
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mechanisms in stroke patients with relatively healthy
hearts may trigger transient paroxysms of lower-burden
AF. Identifying differences between AFDAS and KAF is
important for characterizing the risk of stroke recurrence
and potential differences in the risk/benefit ratio of oral
anticoagulation. In line with this hypothesis, in a population-based study, AFDAS did not entail a higher risk of
stroke recurrence than no AF in fully adjusted models. In
contrast, KAF was associated with 25% increased risk [3].
Based on this evidence, we hypothesized that AFDAS has
a lower prevalence of cardiovascular comorbidities and
structural heart disease and a lower risk of stroke recurrence than KAF [4]. We performed a systematic search
and meta-analysis to compare the characteristics and
prognosis of AFDAS and KAF.

Materials and Methods
The study protocol was developed based on the 2020 Preferred
Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines [5] and is published elsewhere [4]. We performed
a systematic search of articles published until June 30, 2021, including patients with ischemic stroke or transient ischemic attack
(TIA) reporting differences between AFDAS and KAF. We
searched PubMed, Scopus, and EMBASE according to prespecified search terms (online suppl. Tables S1–S3; for all online suppl.
material, see www.karger.com/doi/10.1159/000520101) and study
protocol [4]. We also included all titles listed in the PubMed functions “Similar articles” and “Cited by” (online suppl. Tables S4 and
S5). Two authors screened all titles (A.J-.R. and L.A.S.) and handled differences by consensus. To be included, studies had to comprise patients with a diagnosis of ischemic stroke or TIA reporting
any of the following data: demographics (age and sex), risk factors
(hypertension, diabetes mellitus, dyslipidemia, and CHA2DS2VASc score), vascular comorbidities (coronary artery disease, congestive heart failure, prior myocardial infarction, peripheral artery
disease, previous stroke, or TIA), chronic kidney disease, cardiac
structural characteristics (left atrial diameter and left ventricular
ejection fraction), stroke severity (National Institutes of Health
Stroke Scale), insular cortex involvement, and outcomes (stroke
recurrence and death) in groups with AFDAS and KAF. We excluded review articles, letters to the editor, editorial articles, conference papers with incomplete information, studies with small
sample sizes (<30 subjects), and publications with duplicated cohorts or without information an any of the variables specified in
the inclusion criteria. Data extraction was performed by a single
author (L.A.S.), subsequently audited by a second author (S.F.) and
additionally reviewed twice by a single author (L.A.S.). We initially planned to perform fixed or random effects meta-analyses
depending on heterogeneity (random-effects analyses when I2 was
>40%) [4, 6]. However, we found that study populations, diagnostic methods, and the setting of the clinical diagnosis of AFDAS
were substantially diverse, suggesting that heterogeneity was present in all analyses despite low I2 statistics. As such, we performed
random-effect models for all variables to obtain more reliable and
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conservative estimates. Additionally, we performed fixed-effect
analyses for variables with I2 <40% to identify potential inconsistencies. Performing random-effect models for all variables was also
considered as a way to avoid assigning a disproportionate weight
to a few larger studies, since random-effect analyses give relatively
more weight to smaller studies than fixed-effects approaches [6].
We estimated odds ratios (OR) and 95% confidence intervals (95%
CI) for dichotomic variables and standardized mean differences
(SMD) for continuous variables. We stratified the magnitude of
SMD (Cohen’s d) into small (d = 0.2), medium (d = 0.5), and large
(d = 0.8) [7]. As prespecified in the study protocol, we applied the
“leave-one-out” procedure, influence analyses, and graphical display of study heterogeneity (GOSH) plots to account for sources
of heterogeneity for variables with ≥10 studies and high heterogeneity (I2 >40%) [4]. As sensitivity analyses, we generated additional estimates after excluding studies identified as outliers and causing significant heterogeneity. We evaluated differences between
AFDAS and KAF in variables comprised in the inclusion criteria.
We used funnel plots to assess publication bias. We applied the
Critical Appraisal Checklist for cohort, case-control, and observational studies to evaluate the risk of bias [8]. We used this tool instead of the one originally stated in the study protocol because it
has a greater versatility for assessing different types of studies. The
risk of bias was assessed by a single author (J.C.V.-G.) and audited
by a second author (L.A.S.). We did not perform meta-analyses for
variables reported in <3 studies. We performed all analyses with R
V.3.6.2 (“Meta” and “Metaphor” packages). Most of the data used
in this study are available in the online supplementary file. Full
datasets will be made available upon reasonable request.

Results

After screening 33,795 titles, we included 21 studies
comprising 22,566 patients (online suppl. Fig. S1). Hypertension (OR 0.79, 95% CI: 0.68, 0.92; 16 studies; I2 =
34%), dyslipidemia (OR 0.82, 95% CI: 0.73, 0.92; 11 studies; I2 = 0%), coronary artery disease (OR 0.50, 95% CI:
0.42, 0.61; 8 studies; I2 = 48%), prior myocardial infarction (OR 0.60, 95% CI: 0.46, 0.79; 5 studies; I2 = 7%), congestive heart failure (OR 0.37, 95% CI: 0.31, 0.44; 12 studies; I2 = 17%), peripheral artery disease (OR 0.44, 95% CI:
0.29, 0.68; 7 studies; I2 = 68%), previous stroke (OR 0.38,
95% CI: 0.25, 0.58; 5 studies; I2 = 43%), and previous
stroke or TIA (OR 0.57, 95% CI: 0.42, 0.77; 4 studies; I2
= 0%) were significantly less prevalent in AFDAS than in
KAF (Fig. 1a; online suppl. Fig. S2, S3, S5–S10). The
CHA2DS2-VASc score was 50% lower in patients with
AFDAS than in those with KAF (SMD −0.47 95% CI:
−0.60, −0.34; 9 studies, I2 = 0%) (Fig. 1b; online suppl.
Fig. S4). Mean left atrial diameter was smaller (SMD
−0.65, 95% CI: −0.99 to −0.31; 5 studies; I2 = 41%) and
the left ventricular ejection fraction was larger (SMD
0.25, 95% CI: 0.20–0.30; 5 studies; I2 = 0%) in AFDAS
Cerebrovasc Dis 2022;51:152–157
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a

b

Fig. 1. Summary measures of all meta-analyses comparing AFDAS and KAF. AFDAS, atrial fibrillation detected

after stroke; KAF, known atrial fibrillation; NIHSS, National Institutes of Health Stroke Scale; TIA, transient
ischemic attack.
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Table 1. Main characteristics of included studies [3, 9, 10, 14–31]
Study

IS or TIA

N

Design

Screening method

Setting

Duration of follow-up

Vingerhoets et al. [9]
Gonzalez-Toledo et al. [10]
Palm et al. [15]
Ward et al. [16]
Baturova et al. [14]
Jaakkola et al. [17]
Kim et al. [18]
Rizos et al. [19]
Borowsky et al. [20]
Muscari et al. [21]
Rizos et al. [22]
Shiroto et al. [23]
Yang et al. [24]
Hsieh et al. [25]
Sposato et al. [3]
Krawczyk et al. [26]
Li et al. [27]
Yang et al. [28]
Ziegler et al. [29]
Bhatla et al. [30]
Watanabe et al. [31]

IS*
IS
IS
IS/TIA
IS
IS/TIA
IS
IS
IS
IS
IS
IS
IS/TIA
IS
IS
IS
IS
IS
IS
IS
IS

202
87
178
87
134
3,623
352
320
856
256
64
1,161
7,491
243
1,877
23
504
196
352
320
856

Cross-sectional
Cross-sectional
Cross-sectional
Cross-sectional
Case-control
Cohort
Cross-sectional
Cross-sectional
Cross-sectional
Cross-sectional
Cross-sectional
Cross-sectional
Cross-sectional
Cohort
Cohort
Cohort
Cross-sectional
Cohort
Cross-sectional
Cohort
Cross-sectional

CEM
CEM
ECG and Holter
ECG and CEM
MCOT
ECG and CEM
na
ECG, Holter, CEM
ECG, Holter, ICT
CEM
ECG, Holter, CEM
ECG, Holter, CEM
Holter
na
ECG, ICT, Holter
ECG, ICT, Holter
Holter
ECG, ICT, Holter
Holter, ELR
ECG, Holter
ECG, Holter

IP
IP
na
IP
OP
IP
IP/OP
IP
IP/OP
IP
IP
IP
IP
IP
IP/OP
IP/OP
IP
IP
IP
IP/OP
IP

na
na
na
na
na
30 days
na
na
na
na
na
na
na
1 year
1 year
5.5 years
na
1 year
>1 year
4.9 years
na

Online supplementary Table S6 (online suppl. material) summarizes the demographic characteristics and baseline risk factors of patients
included in all studies. CEM, continuous inpatient electrocardiographic monitoring; ECG, admission or inhospital electrocardiogram; ELR,
external loop recorder; ICT, inhospital cardiac telemetry; IP, inpatient; IS, ischemic stroke; MCOT, mobile cardiac outpatient telemetry; OP,
outpatient; TIA, transient ischemic attack. * Ten patients had an intracerebral hemorrhage.

than in KAF patients (Fig. 1b; online suppl. Fig. S11 and
S12). AFDAS was associated with a 26% lower risk of
stroke recurrence than KAF (OR 0.74, 95% CI: 0.58–0.95;
3 studies; I2 = 0%) (Fig. 1a; online suppl. Fig. S12). The
absolute risk difference between AFDAS and KAF was
−2.6% (95% CI: −3.7 to −1.6%). There were no differences between AFDAS and KAF in the remaining prespecified variables (online suppl. Fig. S13–S19). We were
unable to perform a meta-analysis for insular cortex involvement because we only identified 2 publications reporting differences between AFDAS and KAF [9, 10].
The risk of bias was overall high. Among 6 cohort studies,
there was one in which the risk of bias was high because
no strategies for addressing confounding were described
(online suppl. Fig. S20). We included only 1 case-control
study, which showed only moderate concern of risk of
bias (online suppl. Fig. S21). Among 14 cross-sectional
studies, 11 evidenced at least 1 criterion for risk of bias
(online suppl. Fig. S22). Fixed-effect models applied to
variables with I2 > 40% showed no differences relative to
random-effect models (online suppl. material).
Atrial Fibrillation Detected after Stroke

Discussion

We found that the prevalence of vascular risk factors,
the CHA2DS2-VASc score, and cardiovascular comorbidities were consistently and significantly lower in AFDAS than in KAF. Patients with AFDAS also had a
smaller left atrial diameter and higher left ventricular
ejection fraction. These findings suggest that patients
with AFDAS may have a relatively more benign vascular profile than those with KAF, explaining the lower
risk of stroke recurrence. The healthier vascular profile
and less severe structural heart disease may explain the
reported lower burden of AF in AFDAS patients [11],
which in turn may further contribute to the lower risk
of stroke recurrence. These findings are mostly based
on pooled data from retrospective observational studies
and thus require further confirmation in prospective
studies comparing AFDAS and KAF characteristics and
outcomes.
As hypothesized previously [1, 2], differences between
AFDAS and KAF can be explained by their distinctive
Cerebrovasc Dis 2022;51:152–157
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pathophysiologies and AF screening strategies. Some AFDAS may constitute preexisting AFs diagnosed only after
stroke and may bear a similar risk profile as KAF. Other
AFDAS may also be preexistent but not causally associated with the stroke and incidentally diagnosed on prolonged cardiac monitoring in patients with a competing
embolic (e.g., carotid artery disease) or atherothrombotic
(e.g., small vessel disease) mechanisms. The Stroke of
Known Cause and Underlying Atrial Fibrillation
(STROKE AF) study, where AFDAS was found in 12.4%
of patients with noncardioembolic events at 12 months,
supports that AFDAS may not always have a causal role
[12]. Regardless of the lack of a causal association between some AFDAS and the related stroke, these arrhythmias may still bear a high risk of stroke that requires close
follow-up and optimized medical management. Additionally, the lower prevalence of cardiovascular comorbidities and less severe structural heart disease of AFDAS
relative to KAF may be explained by stroke-related neurogenic mechanisms lowering the cardiac arrhythmogenesis threshold through autonomic dysregulation and inflammation [2]. This may occur even in individuals with
apparently healthier hearts, as shown in this meta-analysis. In line with this hypothesis, 2 studies showed 3–4×
higher frequency of insular strokes in AFDAS relative to
KAF, supporting a role for autonomic dysregulation [9,
10].
We hypothesize that AFDAS represents an early stage
of AF relative to KAF that becomes evident either because
of prolonged cardiac monitoring (e.g., low-burden AF
that would remain otherwise diagnosed) or because of being triggered by neurogenic mechanisms (e.g., non-AF
atrial substrate that evolves to low-burden AF because of
stroke-related neurogenic mechanisms).
Considering that cardiovascular events are a common
cause of death in stroke patients, we do not have a robust
explanation for the lack of differences in mortality between AFDAS and KAF despite a substantially lower burden of vascular disease in the former group. We hypothesize that the risk of death in both types of AF is mainly
stroke driven rather than instigated by other vascular comorbidities.
This study has limitations. Given the unusually large
number of studies screened, we were unable to document
the reason for the exclusion of the 33,774 studies that
were not included in the analyses. We reported differences in left atrial diameter between AFDAS and KAF
because this was the most consistently used measure
across studies. However, other measures such as the left
atrial volume index are more reliable predictors of cardio156
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vascular outcomes than left atrial diameter [13]. Despite
this, in studies in which left atrial volume index and left
atrial area were reported, sizes were consistently larger in
KAF than in AFDAS patients [10, 14]. When estimating
stroke recurrence and death, we pooled unadjusted ORs
(Table 1). Adjusting these results for relevant variables
such as oral anticoagulation may have yielded different
results. Additionally, the number of studies included in
the estimate for stroke recurrence was relatively low (n =
3).
Conclusion

AFDAS is possibly a different type of arrhythmia than
KAF, with a lower burden of vascular comorbidities and
risk of recurrent stroke. These findings require further
prospective testing.
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